stoxline Quote Chart Rank Option Currency Glossary
  
Akouos, Inc. (AKUS)
13.29  0 (0%)    11-30 16:00
Open: 13.2
High: 13.33
Volume: 1,790,496
  
Pre. Close: 13.29
Low: 13.16
Market Cap: 0(M)
Technical analysis
2023-01-06 4:29:05 PM
Short term     
Mid term     
Targets 6-month :  15.61 1-year :  15.88
Resists First :  13.37 Second :  13.6
Pivot price 13.24
Supports First :  13 Second :  10.81
MAs MA(5) :  13.28 MA(20) :  13.28
MA(100) :  7.75 MA(250) :  6
MACD MACD :  0.3 Signal :  0.5
%K %D K(14,3) :  64.2 D(3) :  54.5
RSI RSI(14): 71.3
52-week High :  13.6 Low :  2.31
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AKUS ] has closed below upper band by 30.6%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.32 - 13.39 13.39 - 13.44
Low: 13.1 - 13.2 13.2 - 13.27
Close: 13.16 - 13.3 13.3 - 13.41
Company Description

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headline News

Thu, 01 Dec 2022
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases | Eli Lilly and Company - Investors | Eli Lilly and Company

Wed, 30 Nov 2022
Lilly and Akouos Announce Expiration of Akouos Tender Offer | Eli Lilly and Company - Investors | Eli Lilly and Company

Wed, 19 Oct 2022
Akouos (AKUS) Surges on $610M Buyout Deal With Eli Lilly - Yahoo Finance

Tue, 18 Oct 2022
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss - PR Newswire

Wed, 17 Nov 2021
Akouos Inc and Blueprint Genetics Announce Resonate Program - The Hearing Review

Sat, 13 Nov 2021
Akouos' AK-OTOF Receives Orphan Drug Designation - The Hearing Review

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 37 (M)
Shares Float 19 (M)
Held by Insiders 1.1 (%)
Held by Institutions 104.8 (%)
Shares Short 828 (K)
Shares Short P.Month 2,280 (K)
Stock Financials
EPS -2.83
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.9
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -22.3 %
Return on Equity (ttm) -42.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.45
Qtrly Earnings Growth 0 %
Operating Cash Flow -74 (M)
Levered Free Cash Flow -60 (M)
Stock Valuations
PE Ratio -4.7
PEG Ratio -0.2
Price to Book value 2.71
Price to Sales 0
Price to Cash Flow -6.63
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android